Unity Biotechnology (UBX) shares were down nearly 30% in recent trading on Monday after the company said UBX1325, its diabetic macular edema treatment for patients with poor vision, did not achieve statistical non-inferiority at the primary analysis endpoint in the phase 2b Aspire study.
The company said UBX1325 was non-inferior to aflibercept at week 24 with a confidence interval above 90% but did not meet statistical non-inferiority on the average of weeks 20 and 24, reaching an 88% confidence interval instead of the pre-specified 90% threshold.
Unity Biotechnology posted topline results from all participants through 24 weeks and expects complete 36-week data results in Q2.
Price: 1.28, Change: -0.55, Percent Change: -29.86
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。